World J Mens Health.
2023 Jul;41(3):692-700. 10.5534/wjmh.220112.
Efficacy and Safety of Maca (Lepidium meyenii) in Patients with Symptoms of Late-Onset Hypogonadism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Shin D1
- Jeon SH2
- Piao J2
- Park HJ2
- Tian WJ3
- Moon DG4
- Ahn ST4
- Jeon KH5
- Zhu GQ6
- Park I7
- Park HJ8
- Bae WJ1,2
- Cho HJ1
- Hong SH1
- Kim SW
1,2,9
- Affiliations
-
- 1Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Catholic Integrative Medicine Research Institute, The Catholic University of Korea, Seoul, Korea
- 3Department of Urology, The Second Hospital of Jilin University, Chang Chun, China
- 4Department of Urology, Korea University College of Medicine, Seoul, Korea
- 5College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea
- 6Department of Urology, Affiliated Hospital of Qingdao University, Qingdao, China
- 7Yuhan Care Co., Ltd., Yuhan Care R&D Center, Yongin, Korea
- 8Yuhan Care Co., Ltd., Yuhan Natural Product R&D Center, Andong, Korea
- 9Green Medicine Co., Ltd, Busan, Korea
- KMID: 2543324
- DOI: http://doi.org/10.5534/wjmh.220112
Abstract
- Purpose
To evaluated the efficacy and safety of gelatinized Maca (Lepidium meyenii) for eugonadal patients with late onset hypogonadism symptoms (LOH).
Materials and Methods
Participants were instructed to receive 1,000 mg of Maca or placebo, two pills at a time, three times per day for 12 weeks before food intake. To evaluate the efficacy of the drug, Aging Males’ Symptoms scale (AMS), Androgen Deficiency in the Aging Males (ADAM), International Prostate Symptom Score (IPSS), and International Index of Erectile Function (IIEF) questionnaires, serologic tests (total testosterone and free testosterone, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride), body weight, and waist circumference were assessed at 4 and 12 weeks after treatment.
Results
A total of 80 participants were enrolled and randomly assigned to Maca treated group (n=41) or the placebo group (n=39). AMS, IIEF, and IPSS were significantly (p<0.05) improved in Maca treated group than in the placebo group. ADAM positive rate was also significantly (p<0.0001) decreased in Maca treated group.
Conclusions
Maca may be considered an effective and safe treatment for eugonadal patients with late onset hypogonadism symptoms.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Safety of 5-Aminolevulinic Acid for Patients with Symptoms of Late-Onset Hypogonadism: A Preliminary Study
- Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
- Efficacy and Safety of Low-Dose Gamma-Aminobutyric Acid From Unpolished Rice Germ as a Health Functional Food for Promoting Sleep: A Randomized, Double-Blind, Placebo-Controlled Trial
- Adjuvant Sertraline Treallnent for Chronic Schizophrenia :A Randomized, Double Blind, Placeho-Controlled Study
- Efficacy and Safety of New Prokinetic Agent Benachio Q Solution(R) in Patients with Postprandial Distress Syndrome Subtype in Functional Dyspepsia: A Single-center, Randomized, Double-blind, Placebo-controlled Pilot Study
